Drugs / HS-10517
last change Jun 2023 re-read 2 minutes ago

HS-10517

Developed for
COVID-19
Investigated by
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05779579 Feb → May 2023 COVID-19 Jiangsu Hansoh Pharmaceutical Co., Ltd. Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HS-10517 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05779579